- Author: Jasvinder Chawla, MD, MBA; Chief Editor: Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS more...
Hyperammonemia is a metabolic condition characterized by elevated levels of ammonia in the blood. Increased entry of ammonia to the brain is a primary cause of neurologic disorders, such as congenital deficiencies of urea cycle enzymes, hepatic encephalopathies, Reye syndrome, several other metabolic disorders, and some toxic encephalopathies.
Signs and symptoms
Signs and symptoms of early-onset hyperammonemia (neonates) may include the following:
Hyperventilation, grunting respiration
Signs and symptoms of late-onset hyperammonemia (later in life) may include the following:
Failure to thrive
Recurrent Reye syndrome
Rarely, episodic headaches and cyclic vomiting
See Clinical Presentation for more detail.
No specific physical findings are associated with hyperammonemia. Affected infants usually present with the following:
Examination occasionally reveals a peculiar finding, such as odor of "sweaty feet" in isovaleric acidemia or abnormally fragile hair in argininosuccinic aciduria. Infants with argininosuccinic lyase deficiency may present with hepatomegaly.
Perform the following tests in patients with suspected hyperammonemia:
Arterial blood gas analysis
Serum amino acid levels
Urinary orotic acid levels
Urinary ketone tests
Plasma and urinary organic acid levels
DNA mutation analysis: Method of choice to confirm the diagnosis of urea cycle disorders 
Heterozygote identification in ornithine transcarbamoylase deficient pedigrees
The following imaging studies may be used in evaluating patients with hyperammonemia:
Neuroimaging: CT or MRI of the brain
See Workup for more detail.
The therapeutic aims in patients with hyperammonemia are to correct the biochemical abnormalities and ensure adequate nutritional intake. Treatment involves compounds that increase the removal of nitrogen waste.
Medications used in the treatment of hyperammonemia include the following:
Urea cycle disorder treatment agents (eg, sodium phenylbutyrate, carglumic acid, sodium phenylacetate, and sodium benzoate)
Antiemetic agents (eg, ondansetron, granisetron, palonosetron, dolasetron)
Other management approaches for hyperammonemia include the following:
Cessation of protein and/or nitrogen intake
Supportive care with parenteral intake of calories
Surgical intervention for patients with hyperammonemia include liver transplantation for correction of the metabolic error and/or liver cell transplantation as an alternative or bridge to liver transplantation.[2, 3]
Ammonia is a normal constituent of all body fluids. At physiologic pH, it exists mainly as ammonium ion. Reference serum levels are less than 35 µmol/L. Excess ammonia is excreted as urea, which is synthesized in the liver through the urea cycle. Sources of ammonia include bacterial hydrolysis of urea and other nitrogenous compounds in the intestine, the purine-nucleotide cycle and amino acid transamination in skeletal muscle, and other metabolic processes in the kidneys and liver.
Increased entry of ammonia to the brain is a primary cause of neurological disorders associated with hyperammonemia, such as congenital deficiencies of urea cycle enzymes, hepatic encephalopathies, Reye syndrome, several other metabolic disorders, and some toxic encephalopathies.
Ammonia is a product of the metabolism of proteins and other compounds, and it is required for the synthesis of essential cellular compounds. However, a 5- to 10-fold increase in ammonia in the blood induces toxic effects in most animal species, with alterations in the function of the central nervous system.
Both acute and chronic hyperammonemia result in alterations of the neurotransmitter system.
Based on animal study findings, the mechanism of ammonia neurotoxicity at the molecular level has been proposed. Acute ammonia intoxication in an animal model leads to increased extracellular concentration of glutamate in the brain and results in activation of the N -methyl D-aspartate (NMDA) receptor. Activation of this receptor mediates ATP depletion and ammonia toxicity; sustained blocking of the NMDA receptor by continuous administration of antagonists dizocilpine (MK-801) or memantine prevents both phenomena, leading to significantly increased survival time in rats. The ATP depletion is due to activation of Na+/K+ -ATPase, which, in turn, is a consequence of decreased phosphorylation by protein kinase C. Activation of the NMDA receptor is probably the cause of seizures in acute hyperammonemia.
Neuropathologic evaluation demonstrates alteration in the astrocyte morphology. Studies demonstrated a significant downregulation of the gap–junction channel connexin 43, the water channel aquaporin 4 genes, and the astrocytic inward-rectifying potassium channel genes, colocalized to astrocytic end-feet at the brain vasculature, where they regulate potassium and water transport. A downregulation of these channels in hyperammonemic mice suggests an alteration in astrocyte-mediated water and potassium homeostasis in the brain as a potential key factor in the development of brain edema.
Also, studies on cultured astrocytes examined the potential role of p53, a tumor suppressor protein and a transcriptional factor, in ammonia-induced neurotoxicity. Activation of p53 contributes to astrocyte swelling and glutamate uptake inhibition, leading to brain edema. Both processes are blocked by p53 inhibition.
High levels of ammonia induce other metabolic changes that are not mediated by activation of the NMDA receptor and thus are not involved directly in ammonia-induced ATP depletion or neurotoxicity. These include increases in brain levels of lactate, pyruvate, glutamine, and free glucose, and decreases in brain levels of glycogen, ketone bodies, and glutamate.
Chronic hyperammonemia is associated with an increase in inhibitory neurotransmission as a consequence of 2 factors. The first is downregulation of glutamate receptors secondary to excessive extrasynaptic accumulation of glutamate. In addition, changes in the glutamate-nitric oxide-cGMP pathway result in impairment of signal transduction associated with NMDA receptors, leading to alteration in cognition and learning. The second is an increased GABAergic tone resulting from benzodiazepine receptor overstimulation by endogenous benzodiazepines and neurosteroids. These changes probably contribute to deterioration of intellectual function, decreased consciousness, and coma. Treatment of chronic hyperammonemic rats with inhibitors of phosphodiesterase 5 restores the function of glutamate-nitric oxide-cGMP pathway and cGMP levels in rats’ brain, with restored ability to learn a conditional task.
RNA oxidation offers an explanation for multiple disturbances of neurotransmitter system, gene expression, and secondary cognitive deficiencies noticed in hepatic encephalopathy. In chronic hepatic encephalopathies, a small-grade astrocyte swelling was observed without overt brain edema. Astrocyte edema produces reactive oxygen and nitrogen oxide species, resulting in RNA oxidation and increased of free intracellular zinc. RNA oxidation may impair synthesis of postsynaptic proteins involved in learning and memory consolidation.
Ammonia also increases the transport of aromatic amino acids (eg, tryptophan) across the blood-brain barrier. This leads to an increase in the level of serotonin, which is the basis for anorexia in hyperammonemia.
Collecting accurate data on the frequency of metabolic disorders is difficult, because the information collected is representative of the particular area or the population group; the incidence of urea cycle disorders in the United States is estimated at 1 in 25,000 live births.
The prevalence of urea cycle disorders is currently estimated at 1:8,000-1:44,000 births internationally. The prevalence may be underestimated due to underdiagnosis of fatal cases and unreliable newborn screening.
Coma and cerebral edema are the major causes of death; the survivors of coma have a high incidence of intellectual impairment.
These disorders have been observed in all races.
All the urea cycle disorders are inherited in an autosomal recessive pattern, except ornithine transcarbamoylase (OTC) deficiency, which is inherited as an X-linked trait; however, female carriers of the OTC gene can become symptomatic.
Early-onset hyperammonemia presents in the neonatal period. Urea cycle disorders can present later in life (see History).
Haeberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, et al. Suggested Guidelines for the Diagnosis and Management of Urea Cycle Disorders. Orphanet J Rare Dis. 2012 May 29. 7(1):32. [Medline].
Meyburg J, Das AM, Hoerster F, Lindner M, Kriegbaum H, Engelmann G, et al. One liver for four children: first clinical series of liver cell transplantation for severe neonatal urea cycle defects. Transplantation. 2009 Mar 15. 87(5):636-41. [Medline].
Meyburg J, Schmidt J, Hoffmann GF. Liver cell transplantation in children. Clin Transplant. 2009 Dec. 23 Suppl 21:75-82. [Medline].
Rodrigo R, Cauli O, Boix J, ElMlili N, Agusti A, Felipo V. Role of NMDA receptors in acute liver failure and ammonia toxicity: therapeutical implications. Neurochem Int. 2009 Jul-Aug. 55(1-3):113-8. [Medline].
Lichter-Konecki U, Mangin JM, Gordish-Dressman H, Hoffman EP, Gallo V. Gene expression profiling of astrocytes from hyperammonemic mice reveals altered pathways for water and potassium homeostasis in vivo. Glia. 2008 Mar. 56(4):365-77. [Medline].
Panickar KS, Jayakumar AR, Rao KV, Norenberg MD. Ammonia-induced activation of p53 in cultured astrocytes: role in cell swelling and glutamate uptake. Neurochem Int. 2009 Jul-Aug. 55(1-3):98-105. [Medline].
Llansola M, Rodrigo R, Monfort P, Montoliu C, Kosenko E, Cauli O, et al. NMDA receptors in hyperammonemia and hepatic encephalopathy. Metab Brain Dis. 2007 Dec. 22(3-4):321-35. [Medline].
Monfort P, Cauli O, Montoliu C, Rodrigo R, Llansola M, Piedrafita B, et al. Mechanisms of cognitive alterations in hyperammonemia and hepatic encephalopathy: therapeutical implications. Neurochem Int. 2009 Jul-Aug. 55(1-3):106-12. [Medline].
Schliess F, Görg B, Häussinger D. RNA oxidation and zinc in hepatic encephalopathy and hyperammonemia. Metab Brain Dis. 2009 Mar. 24(1):119-34. [Medline].
Summar ML, Dobbelaere D, Brusilow S, Lee B. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr. 2008 Oct. 97(10):1420-5. [Medline]. [Full Text].
Ichikawa K, Gakumazawa M, Inaba A, Shiga K, Takeshita S, Mori M, et al. Acute encephalopathy of Bacillus cereus mimicking Reye syndrome. Brain Dev. 2009 Sep 29. [Medline].
Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila). 2009 Feb. 47(2):101-11. [Medline].
DeWolfe JL, Knowlton RC, Beasley MT, Cofield S, Faught E, Limdi NA. Hyperammonemia following intravenous valproate loading. Epilepsy Res. 2009 Jul. 85(1):65-71. [Medline].
Cheung E, Wong V, Fung CW. Topiramate-valproate-induced hyperammonemic encephalopathy syndrome: case report. J Child Neurol. 2005 Feb. 20(2):157-60. [Medline].
Deutsch SI, Burket JA, Rosse RB. Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate. Clin Neuropharmacol. 2009 Nov-Dec. 32(6):350-2. [Medline].
Tantikittichaikul S, Johnson J, Laengvejkal P, DeToledo J. Topiramate-induced hyperammonemic encephalopathy in a patient with mental retardation: A case report and review of the literature. Epilepsy Behav Case Rep. 2015. 4:84-5. [Medline]. [Full Text].
Adler LW, Regenold WT. Valproate-Related Hyperammonemia in Older Adult Psychiatric Inpatients. Prim Care Companion CNS Disord. 2015. 17 (2):[Medline].
Adams EN, Marks A, Lizer MH. Carbamazepine-induced hyperammonemia. Am J Health Syst Pharm. 2009 Aug 15. 66(16):1468-70. [Medline].
Yamamoto Y, Takahashi Y, Imai K, Mishima N, Yazawa R, Inoue K, et al. Risk factors for hyperammonemia in pediatric patients with epilepsy. Epilepsia. 2013 Feb 14. [Medline].
Adatia S, Poladia B, Joshi SR, Panikar V, Chauhan V, Hastak SM. Hyperammonemic coma presenting as Hashimoto's encephalopathy. J Assoc Physicians India. 2008 Dec. 56:989-91. [Medline].
Rimar D, Kruzel-Davila E, Dori G, Baron E, Bitterman H. Hyperammonemic coma--barking up the wrong tree. J Gen Intern Med. 2007 Apr. 22(4):549-52. [Medline].
Lora-Tamayo J, Palom X, Sarrá J, Gasch O, Isern V, Fernández de Sevilla A, et al. Multiple myeloma and hyperammonemic encephalopathy: review of 27 cases. Clin Lymphoma Myeloma. 2008 Dec. 8(6):363-9. [Medline].
Rovira A, Alonso J, Córdoba J. MR imaging findings in hepatic encephalopathy. AJNR Am J Neuroradiol. 2008 Oct. 29(9):1612-21. [Medline].
Zwingmann C. Nuclear magnetic resonance studies of energy metabolism and glutamine shunt in hepatic encephalopathy and hyperammonemia. J Neurosci Res. 2007 Nov 15. 85(15):3429-42. [Medline].
Al-Hassnan ZN, Rashed MS, Al-Dirbashi OY, Patay Z, Rahbeeni Z, Abu-Amero KK. Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome with stroke-like imaging presentation: clinical, biochemical and molecular analysis. J Neurol Sci. 2008 Jan 15. 264(1-2):187-94. [Medline].
Oldham MS, VanMeter JW, Shattuck KF, Cederbaum SD, Gropman AL. Diffusion tensor imaging in arginase deficiency reveals damage to corticospinal tracts. Pediatr Neurol. 2010 Jan. 42(1):49-52. [Medline].
Arbeiter AK, Kranz B, Wingen AM, Bonzel KE, Dohna-Schwake C, Hanssler L, et al. Continuous venovenous haemodialysis (CVVHD) and continuous peritoneal dialysis (CPD) in the acute management of 21 children with inborn errors of metabolism. Nephrol Dial Transplant. 2009 Nov 23. [Medline].
Cardenas JF, Bodensteiner JB. Osmotic Demyelination Syndrome as a Consequence of Treating Hyperammonemia in a Patient With Ornithine Transcarbamylase Deficiency. J Child Neurol. 2009 Feb 18. [Medline].
Thompson CA. Carglumic acid approved to treat genetic hyperammonemia. Am J Health Syst Pharm. 2010 May 1. 67(9):690. [Medline].
Albrecht J. Roles of neuroactive amino acids in ammonia neurotoxicity. J Neurosci Res. 1998 Jan 15. 51(2):133-8. [Medline].
Albrecht J, Jones EA. Hepatic encephalopathy: molecular mechanisms underlying the clinical syndrome. J Neurol Sci. 1999 Nov 30. 170(2):138-46. [Medline].
Batshaw ML. Hyperammonemia. Curr Probl Pediatr. 1984 Nov. 14(11):1-69. [Medline].
Batshaw ML. Inborn errors of urea synthesis. Ann Neurol. 1994 Feb. 35(2):133-41. [Medline].
Becker L, Prior T, Yates A. Metabolic diseases. Textbook of Neuropathology, Baltimore: Williams & Wilkins. 1997. 487.
Berlot G, Battaglia K, Ukmar M. [Hyperammoniemia and central pontine myelinolysis in a patient with Sjögren syndrome and chronic valproate use]. Recenti Prog Med. 2008 Oct. 99(10):502-4. [Medline].
Bhoyar A, Short A. Congenital hypopituitarism associated with hyperammonemia. Indian J Pediatr. 2009 Mar. 76(3):327-8. [Medline].
Bosoi CR, Rose CF. Identifying the direct effects of ammonia on the brain. Metab Brain Dis. 2009 Mar. 24(1):95-102. [Medline].
Breningstall GN. Neurologic syndromes in hyperammonemic disorders. Pediatr Neurol. 1986 Sep-Oct. 2(5):253-62. [Medline].
Brusilow SW, Horwich AL. Urea cycle disorders. The Metabolic and Molecular Bases of Inherited Disease, New York: McGraw-Hill. 1995. 1:1187-1232.
Chung MY, Chen CC, Huang LT, et al. Transient hyperammonemia in a neonate. Acta Paediatr Taiwan. 2005 Mar-Apr. 46(2):94-6. [Medline].
Cohn RM, Roth KS. Hyperammonemia, bane of the brain. Clin Pediatr (Phila). 2004 Oct. 43(8):683-9. [Medline].
Collins FS, Summer GK, Schwartz RP, Parke JC Jr. Neonatal argininosuccinic aciduria-survival after early diagnosis and dietary management. J Pediatr. 1980 Mar. 96(3 Pt 1):429-31. [Medline].
del Rosario M, Werlin SL, Lauer SJ. Hyperammonemic encephalopathy after chemotherapy. Survival after treatment with sodium benzoate and sodium phenylacetate. J Clin Gastroenterol. 1997 Dec. 25(4):682-4. [Medline].
Deodato F, Boenzi S, Rizzo C, et al. Inborn errors of metabolism: an update on epidemiology and on neonatal-onset hyperammonemia. Acta Paediatr Suppl. 2004 May. 93(445):18-21. [Medline].
Diaz GA, Krivitzky LS, Mokhtarani M, Rhead W, Bartley J, Feigenbaum A, et al. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. Hepatology. 2012 Sep 7. [Medline]. [Full Text].
Feillet F, Leonard JV. Alternative pathway therapy for urea cycle disorders. J Inherit Metab Dis. 1998. 21 Suppl 1:101-11. [Medline].
Felipo V, Kosenko E, Minana MD, et al. Molecular mechanism of acute ammonia toxicity and of its prevention by L-carnitine. Adv Exp Med Biol. 1994. 368:65-77. [Medline].
Hamed SA, Abdella MM. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: Relationship to blood carnitine status. Epilepsy Res. 2009 May 13. [Medline].
Hauser ER, Finkelstein JE, Valle D, Brusilow SW. Allopurinol-induced orotidinuria. A test for mutations at the ornithine carbamoyltransferase locus in women. N Engl J Med. 1990 Jun 7. 322(23):1641-5. [Medline].
Jalan R, Lee WM. Treatment of Hyperammonemia in Liver Failure: A Tale of Two Enzymes. Gastroenterology. 2009 Apr 28. [Medline].
Kuntze JR, Weinberg AC, Ahlering TE. Hyperammonemic coma due to Proteus infection. J Urol. 1985 Nov. 134(5):972-3. [Medline].
Logan W. Neonatal hyperammonemic encephalopathy. Topics in Neonatal Neurology, Orlando: Grune & Stratton. 1984. 137-157.
Maestri NE, McGowan KD, Brusilow SW. Plasma glutamine concentration: a guide in the management of urea cycle disorders. J Pediatr. 1992 Aug. 121(2):259-61. [Medline].
McCall M, Bourgeois JA. Valproic acid-induced hyperammonemia: a case report. J Clin Psychopharmacol. 2004 Oct. 24(5):521-6. [Medline].
McGuire PJ, Lee HS, Summar ML. Infectious Precipitants of Acute Hyperammonemia Are Associated with Indicators of Increased Morbidity in Patients with Urea Cycle Disorders. J Pediatr. 2013 Sep 28. [Medline].
Msall M, Batshaw ML, Suss R, et al. Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea-cycle enzymopathies. N Engl J Med. 1984 Jun 7. 310(23):1500-5. [Medline].
Prasad AN, Breen JC, Ampola MG, Rosman NP. Argininemia: a treatable genetic cause of progressive spastic diplegia simulating cerebral palsy: case reports and literature review. J Child Neurol. 1997 Aug. 12(5):301-9. [Medline].
Rajpoot DK, Gargus JJ. Acute hemodialysis for hyperammonemia in small neonates. Pediatr Nephrol. 2004 Apr. 19(4):390-5. [Medline].
Ratnaike RN, Schapel GJ, Purdie G, et al. Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs. Br J Clin Pharmacol. 1986 Jul. 22(1):100-3. [Medline].
Schaefer F, Straube E, Oh J, et al. Dialysis in neonates with inborn errors of metabolism. Nephrol Dial Transplant. 1999 Apr. 14(4):910-8. [Medline].
Schutze GE, Edwards MS, Adham BI, Belmont JW. Hyperammonemia and neonatal herpes simplex pneumonitis. Pediatr Infect Dis J. 1990 Oct. 9(10):749-50. [Medline].
Smith W, Diaz GA, Lichter-Konecki U, Berry SA, Harding CO, McCandless SE, et al. Ammonia Control in Children Ages 2 Months through 5 Years with Urea Cycle Disorders: Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate. J Pediatr. 2013 Jan 13. [Medline].
Smith W, Kishnani PS, Lee B, et al. Urea cycle disorders: clinical presentation outside the newborn period. Crit Care Clin. 2005 Oct. 21(4 Suppl):S9-17. [Medline].
Summar ML, Barr F, Dawling S, et al. Unmasked adult-onset urea cycle disorders in the critical care setting. Crit Care Clin. 2005 Oct. 21(4 Suppl):S1-8. [Medline].
Uchino T, Endo F, Matsuda I. Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. J Inherit Metab Dis. 1998. 21 Suppl 1:151-9. [Medline].
Weng TI, Shih FF, Chen WJ. Unusual causes of hyperammonemia in the ED. Am J Emerg Med. 2004 Mar. 22(2):105-7. [Medline].
Whitington PF, Alonso EM, Boyle JT, et al. Liver transplantation for the treatment of urea cycle disorders. J Inherit Metab Dis. 1998. 21 Suppl 1:112-8. [Medline].
Williams CA, Tiefenbach S, McReynolds JW. Valproic acid-induced hyperammonemia in mentally retarded adults. Neurology. 1984 Apr. 34(4):550-3. [Medline].